Division of Hematology/Oncology, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Department of Pathology, Beth Israel Deaconess Medical Center and Cancer Research Institute, Harvard Medical School, Boston, MA, 02215, USA.
Nat Commun. 2024 Apr 15;15(1):3220. doi: 10.1038/s41467-024-47427-w.
Induced oncoproteins degradation provides an attractive anti-cancer modality. Activation of anaphase-promoting complex (APC/C) prevents cell-cycle entry by targeting crucial mitotic proteins for degradation. Phosphorylation of its co-activator CDH1 modulates the E3 ligase activity, but little is known about its regulation after phosphorylation and how to effectively harness APC/C activity to treat cancer. Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1)-catalyzed phosphorylation-dependent cis-trans prolyl isomerization drives tumor malignancy. However, the mechanisms controlling its protein turnover remain elusive. Through proteomic screens and structural characterizations, we identify a reciprocal antagonism of PIN1-APC/C mediated by domain-oriented phosphorylation-dependent dual interactions as a fundamental mechanism governing mitotic protein stability and cell-cycle entry. Remarkably, combined PIN1 and cyclin-dependent protein kinases (CDKs) inhibition creates a positive feedback loop of PIN1 inhibition and APC/C activation to irreversibly degrade PIN1 and other crucial mitotic proteins, which force permanent cell-cycle exit and trigger anti-tumor immunity, translating into synergistic efficacy against triple-negative breast cancer.
诱导致癌蛋白降解提供了一种有吸引力的抗癌模式。通过靶向关键有丝分裂蛋白进行降解,激活后期促进复合物(APC/C)可防止细胞周期进入。其共激活因子 CDH1 的磷酸化调节 E3 连接酶的活性,但对磷酸化后的调节及其如何有效利用 APC/C 活性来治疗癌症知之甚少。肽基脯氨酰顺反异构酶 NIMA 相互作用 1(PIN1)催化的磷酸化依赖性顺反脯氨酸异构化驱动肿瘤恶性。然而,控制其蛋白质周转的机制仍不清楚。通过蛋白质组学筛选和结构表征,我们发现 PIN1-APC/C 通过基于结构域的磷酸化依赖性双重相互作用的相互拮抗作用是控制有丝分裂蛋白稳定性和细胞周期进入的基本机制。值得注意的是,PIN1 和细胞周期蛋白依赖性激酶(CDKs)的联合抑制作用会形成一个 PIN1 抑制和 APC/C 激活的正反馈循环,从而不可逆地降解 PIN1 和其他关键的有丝分裂蛋白,迫使细胞周期永久退出并引发抗肿瘤免疫,从而转化为针对三阴性乳腺癌的协同疗效。